News

Skin conductance — the electrical activity on the surface of the skin in response to stimuli, as measured using wrist-worn devices — is indicative of changes in emotions and behaviors that affect the autonomic nervous system of Rett syndrome patients, a pilot study reports. Together, these alternations are known as…

A study suggests lower intake of dietary protein is associated with more severe growth deficits in Taiwanese children with Rett syndrome. While dystonia — uncontrolled movements due to muscle contractions — increased with age, it did not affect growth, the scientists…

People with Rett syndrome who grind their teeth during the day had a higher incidence of dental treatment, particularly restorations, than those who did not, an international database study reported.  The findings also showed that patients fed orally had more dental…

More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…

Early administration of a compound intended to enhance signals between brain cells lessened disease severity, and improved overall health and survival in a mouse model of Rett syndrome. The improvements, which also included benefits in nerve cell activity, indicate that treatments enhancing neuronal activity early…

The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each…

An independent monitoring board has recommended that all three ongoing clinical trials of Anavex 2-73 (blarcamesine), an investigational treatment for Rett syndrome, continue without changes, based on a review of interim safety data. Anavex Life Sciences, the medication’s developer, announced the decision in a press release. Data…

Acadia Pharmaceuticals is enrolling participants at four new clinical sites in its Phase 3 LAVENDER trial testing trofinetide as a treatment for girls and young women with Rett syndrome. In an online letter to the Rett community, Acadia announced these recent additions: Seattle Children’s Hospital; the University of North Carolina…